ESA Use In Chronic Kidney Disease Will Get Second MedCAC Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare coverage of Amgen's Aranesp and other erythropoiesis-stimulating agents in chronic kidney disease is the topic for a meeting by the Medicare Evidence Development and Coverage Advisory Committee on Jan. 19.
You may also be interested in...
Pharma News, In Brief
Medicare ESRD Performance Measures
Pharma News, In Brief
Medicare ESRD Performance Measures
Aranesp Awaits Label Transplant As Committee Mulls Alternate Trial Designs
Amgen avoided an immediate setback when a Cardiovascular and Renal Drugs Advisory Committee meeting on Oct. 18 voted against further restrictions on the use of Aranesp (darbepoetin alfa) in chronic kidney disease (CKD) patients.